Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization -105% Improvement Relative Risk c19early.org/a Vaezi et al. IRCT20171219037964N3 Favipiravir RCT EARLY Is early treatment with favipiravir beneficial for COVID-19? Double-blind RCT 77 patients in Iran (December 2020 - March 2021) Higher hospitalization with favipiravir (not stat. sig., p=0.43) Vaezi et al., Advances in Respiratory Medicine, doi:10.3390/arm91010004 Favors favipiravir Favors control
Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial
Vaezi et al., Advances in Respiratory Medicine, doi:10.3390/arm91010004, IRCT20171219037964N3
Vaezi et al., Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind,.., Advances in Respiratory Medicine, doi:10.3390/arm91010004, IRCT20171219037964N3
Jan 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 77 outpatients in Iran, showing increased hospitalization with treatment, without statistical significance. Favipiravir 1600mg daily for five days. 21% of favipiravir patients did not complete treatment.
risk of hospitalization, 105.3% higher, RR 2.05, p = 0.43, treatment 4 of 38 (10.5%), control 2 of 39 (5.1%), day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Vaezi et al., 28 Jan 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 6 authors, study period 5 December, 2020 - 31 March, 2021, trial IRCT20171219037964N3.
Contact: salahimehrdad@yahoo.com (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: Article Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial Atefeh Vaezi 1 , Mehrzad Salmasi 2 , Forogh Soltaninejad 3 , Mehrdad Salahi 4, *, Shaghayegh Haghjooy Javanmard 5 and Babak Amra 3 1 2 3 4 5 * Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran Bamdad Respiratory and Sleep Research Center, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran Department of Infectious Disease, School of Medicine, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran Department of Physiology, Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran Correspondence: salahimehrdad@yahoo.com Highlights: What are the main findings? • Favipiravir, an RNA-dependent RNA polymerase inhibitor, shows no benefit in preventing the hospitalization of mild to moderate COVID-19 patients. What is the implication of the main finding? • Citation: Vaezi, A.; Salmasi, M.; Soltaninejad, F.; Salahi, M.; Javanmard, S.H.; Amra, B. Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. Adv. Respir. Med. 2023, 91, 18–25. https://doi.org/10.3390/arm91010004 Received: 28 November 2022 Revised: 11 January 2023 Accepted: 20 January 2023 Published: 28 January 2023 Copyright: © 2023 by the authors. Our results may inform decisions on the exclusion of Favipiravir from mild to moderate COVID-19 treatment guidelines. Abstract: Background: Finding effective outpatient treatments to prevent COVID-19 progression and hospitalization is necessary and is helpful in managing limited hospital resources. Repurposing previously existing treatments is highly desirable. In this study, we evaluate the efficacy of Favipiravir in the prevention of hospitalization in symptomatic COVID-19 patients who were not eligible for hospitalization. Methods: This study was a triple-blind randomized controlled trial conducted between 5 December 2020 and 31 March 2021 in three outpatient centers in Isfahan, Iran. Patients in the intervention group received Favipiravir 1600 mg daily for five days, and the control group received a placebo. Our primary outcome was the proportion of hospitalized participants from day 0 to day 28. The outcome was assessed on days 3, 7, 14, 21, and 28 through phone calls. Results: Seventy-seven patients were randomly allocated to Favipiravir and placebo groups. There was no significant difference between groups considering baseline characteristics. During the study period, 10.5% of patients in the Favipiravir group and 5.1% of patients in the placebo group were hospitalized, but there was no significant difference between them (p-value = 0.3). No adverse event was reported in the treatment group. Conclusions: Our study shows that Favipiravir did not reduce the hospitalization rate of mild to moderate COVID-19 patients in outpatient settings. Keywords: efficacy; Favipiravir; mild COVID-19; outpatient; SARS-CoV-2 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit